A study commissioned by the Generic Pharmaceutical Association found that settlement payments from pay-for-delay cases result in positive effects for consumers, according to reports. The GPhA announced the findings of the study, performed by Intercontinental Marketing Services, at a press conference. The findings further back regulatory decisions by the US Federal Trade Commission and, more recently, the US Supreme Court, that backed the possibility that the so-called pay-for-delay agreements, which delay the sale of cheaper generic pharmaceuticals so brand names can remain on shelves, can be anticompetitive. Reports say the GPhA’s study found that consumers saved $25.5 billion between 2005 and 2012 through such settlements for 33 different pharmaceutical drugs.
Featured News
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
UK Court Confirms Government Demand for Access to Apple’s Encrypted Data
Nov 19, 2026 by
CPI
UK Competition Watchdog Probes Into OCS’s £3.1 Billion Mitie Deal
Nov 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff